Director Kaitin Kenneth I bought 10,000 shares of CRIS at $0.55 on 2026-03-31; stock down -81.1% from 52-week high.
Director Kaitin Kenneth I purchased 10,000 shares at $0.55, increasing his holdings by 710.7% from 1,407 to 11,407 shares. The company is operating in distress: it reported a net loss of $7,729,000 in its most recent full fiscal year, with revenue declining -13.4% year-over-year and current quarterly revenue of only $3,176,000. The stock has collapsed -81.1% from its 52-week high of $2.80 and is trading -50.9% below its 30-day average. This purchase represents a material commitment by a director in a capital-constrained, loss-making biotech, but occurs after severe deterioration in both the company's financial performance and the stock's valuation. The significance of the buy signal is heavily mitigated by the company's unprofitability, revenue decline, and the sharply depressed stock price context.